๐๏ธ Verified NIH Record โข Updated 2026-04-08
A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis (NCT03069326)
Evaluation of Ruxolitinib And Thalidomide Combination as a Therapy for Patients With Myelofibrosis
๐ต Active, Not Recruiting Phase2 ๐ Investigational Drug / Biologic Sponsor: Memorial Sloan Kettering Cancer Center
๐ฉบ Plain-English Summary (8th-Grade Level)
The purpose of this study is to test any good and bad effects of the study drugs called ruxolitinib and thalidomide. Ruxolitinib and thalidomide could shrink the cancer, but it could also cause side effects.
Who can join: Review the eligibility criteria below.
Location: Memorial Sloan Kettering Monmouth โ Middletown, New Jersey
Age range: 18 Years
๐งช Interventions in This Study
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (7 Sites)
- Memorial Sloan Kettering Monmouth โ Middletown, New Jersey
- Memorial Sloan Kettering Bergen โ Montvale, New Jersey
- Memorial Sloan Kettering Commack โ Commack, New York
- Memorial Sloan Kettering Westchester โ Harrison, New York
- Memorial Sloan Kettering Cancer Center โ New York, New York
- Memorial Sloan Kettering Nassau โ Uniondale, New York
- Md Anderson Cancer Center โ Houston, Texas
๐ Contact the Study Coordinator
Phone: (800) 525-2225
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Myelofibrosis
- Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms โ Birmingham, Alabama
- Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis โ Calgary, Alberta
- Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis โ Birmingham, Alabama
- Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) โ Birmingham, Alabama
- A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis โ Pasadena, California
- A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis) โ Newport Beach, California
Explore by condition: All Myelofibrosis clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.